Inozyme Pharma Inc (INZY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2022 | 06-2022 | 03-2022 | 12-2021 | 09-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -48,517 | -32,145 | -16,884 | -56,624 | -37,870 |
| Depreciation Amortization | -536 | -226 | 102 | 844 | 638 |
| Accounts payable and accrued liabilities | -1,003 | -1,090 | -194 | -675 | -2,482 |
| Other Working Capital | -444 | -622 | 767 | 85 | -2,898 |
| Other Operating Activity | 7,139 | 5,236 | 2,049 | 8,217 | 7,903 |
| Operating Cash Flow | $-43,361 | $-28,847 | $-14,160 | $-48,153 | $-34,709 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -8,257 | -147 | 22,579 | 43,193 | 33,666 |
| PPE Investments | -364 | -217 | -17 | -397 | -357 |
| Investing Cash Flow | $-8,621 | $-364 | $22,562 | $42,796 | $33,309 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 4,050 | 0 | 0 | N/A | N/A |
| Common Stock Issued | 68,738 | 68,573 | 240 | 609 | 598 |
| Financing Cash Flow | $72,788 | $68,573 | $240 | $609 | $598 |
| Exchange Rate Effect | -78 | -58 | -15 | 24 | -9 |
| Beginning Cash Position | 23,670 | 23,670 | 23,670 | 28,394 | 28,394 |
| End Cash Position | 44,398 | 62,974 | 32,297 | 23,670 | 27,583 |
| Net Cash Flow | $20,728 | $39,304 | $8,627 | $-4,724 | $-811 |
| Free Cash Flow | |||||
| Operating Cash Flow | -43,361 | -28,847 | -14,160 | -48,153 | -34,709 |
| Capital Expenditure | -364 | -217 | -17 | -397 | -357 |
| Free Cash Flow | -43,725 | -29,064 | -14,177 | -48,550 | -35,066 |